AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18460478
Drug: Chitosan 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan 4.5 g per day
Trial: 18460478
Drug: Chitosan 6.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan 6.75 g per day
Trial: 18460478
Drug: Glucomannan 6.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucomannan 6.75 g per day
Trial: 18460478
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 g chitosan)
Trial: 11818160
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of AVA 4 weeks apart IM
Trial: 11818160
Drug: IM administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IM administration of AVA
Trial: 11818160
Drug: SQ administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SQ administration of AVA
Trial: 11818160
Drug: Longer dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer dose interval between first two doses
Trial: 10223393
Drug: Supportive recall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive recall treatments at 3-month intervals
Trial: 10223393
Drug: Supportive recall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive recall treatments at 6-month intervals
Trial: 10223393
Drug: Supportive recall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive recall treatments at 12-month intervals
Trial: 10223393
Drug: Supportive recall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive recall treatments at 18-month intervals
Trial: 10223393
Drug: Supportive recall
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive recall treatments (all groups)
Trial: 7742152
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tablet of 882C87
Trial: 7742152
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg i.v. of 882C87
Trial: 7742152
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of [14C]-882C87
Trial: 2038185
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 1 liter of saline
Trial: 7046543
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide and oral azathioprine (Group 2)
Trial: 7046543
Drug: Boluses of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boluses of intravenous cyclophosphamide (Group 3)
Trial: 31603998
Drug: Transdermal 17β-estradiol
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal 17β-estradiol patch (PATCH) with 200 mg cyclic oral micronized progesterone
Trial: 31603998
Drug: Combined 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined 30 μg ethinyl estradiol and 0.15 mg desogestrel pill (PILL)
Trial: 31603998
Drug: Transdermal 17β-estradiol
RxNorm normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal 17β-estradiol patch (PATCH)
Trial: 31594740
Drug: Sedative use
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedative use
Trial: 17786707
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further therapy (chemotherapy-only group)
Trial: 9690541
Drug: IFN-alpha, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha, 3 x 10(6) IU three times weekly by subcutaneous injection for 36 months or until melanoma recurrence
Trial: 7654890
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg daily followed by no maintenance treatment (OM)
Trial: 7654890
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg daily plus cisapride 5 mg t.d.s. followed by cisapride 5 mg t.d.s. maintenance treatment (OMCIS)
Trial: 7654890
Drug: Cisapride 5
RxNorm normalized name: cisapride 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 5 mg t.d.s. maintenance treatment
Trial: 7654890
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg daily plus cisapride 5 mg t.d.s. (OMCIS)
Trial: 26148680
Drug: Phytosterols 2
RxNorm normalized name: phytosterols 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterols 2 g
Trial: 26148680
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Pravastatin 40 mg and Phytosterols 2 g)
Trial: 23177167
Drug: Corticosteroid (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (40 mg triamcinolone)
Trial: 23177167
Drug: NSAID (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID (60 mg ketorolac)
Trial: 19428882
Drug: MMR and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR and varicella vaccines (separate injections)
Trial: 15504187
Drug: 0.4% end‐tidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% end‐tidal sevoflurane inhalation
Trial: 15504187
Drug: 0.7% end‐tidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7% end‐tidal sevoflurane inhalation
Trial: 15504187
Drug: 2.0% end‐tidal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0% end‐tidal sevoflurane inhalation
Trial: 11050521
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia started before surgery (12 patients received epidural mepivacaine 20 mg mL(‐1) and morphine perioperatively)
Trial: 11050521
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia started after surgery (14 patients received an epidural bolus of bupivacaine 2.5 mg mL(‐1) and morphine after skin closure)
Trial: 11050521
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (bupivacaine 2.5 mg mL(‐1) with morphine administered for three postoperative days)
Trial: 9493700
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (40 mg sustained-release twice daily)
Trial: 2906874
Drug: Ketanserin +
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin + beta-blocker
Trial: 2906874
Drug: Ketanserin +
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin + diuretic
Trial: 28284557
Drug: Binimetinib 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Binimetinib 45 mg orally twice daily
Trial: 28284557
Drug: Dacarbazine 1000
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine 1000 mg/m2 intravenously every 3 weeks
Trial: 18004988
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg tegaserod bid
Trial: 20803855
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg of isobaric bupivacaine with 25 microg of fentanyl and 100 microg of morphine
Trial: 20803855
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of isobaric bupivacaine with 25 microg of fentanyl and 100 microg of morphine
Trial: 16253158
Drug: Low-dose perindopril
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose perindopril (2 mg/d initially, increased to 2-4 mg/d)
Trial: 16253158
Drug: High-dose perindopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose perindopril (2 mg/d initially, increased to 8-10 mg/d)
Trial: 12140470
Drug: Topical vitamin
RxNorm normalized name: vitamin A Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vitamin K cream applied after laser treatment
Trial: 12140470
Drug: Placebo (vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle cream) applied after laser treatment
Trial: 12140470
Drug: Topical vitamin
RxNorm normalized name: vitamin A Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical vitamin K cream applied before laser treatment
Trial: 12140470
Drug: Placebo (vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle cream) applied before laser treatment
Trial: 9874863
Drug: EACA (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EACA (150 mg/kg, i.v. before CPB)
Trial: 9874863
Drug: PRP-EACA (PRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP-EACA (PRP 10 ml/kg harvested with a plasma saver followed by i.v. EACA 150 mg/kg)
Trial: 7751850
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and aggressive management of modifiable risk factors
Trial: 2658918
Drug: Intravenous ceftriaxone‐metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone‐metronidazole preparation
Trial: 47638
Drug: Hydromorphone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (4 mg i.v.)
Trial: 47638
Drug: Methadone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (100 mg p.o. daily)
Trial: 30885518
Drug: Daily sunscreen
RxNorm normalized name: ZINC OXIDE 220 mg in 1 mL TOPICAL CREAM [SPF 30 Daily Sunscreen]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sunscreen use for 4.5 years
Trial: 27578624
Drug: Pharmacist-led medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medication reconciliation and charting service
Trial: 23702931
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg MK-4 daily
Trial: 17261383
Drug: Interferon alfa-2a
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2a treatment for 24 months
Trial: 17261383
Drug: Interferon alfa-2a
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2a treatment
Trial: 9554266
Drug: Nasal OMV
RxNorm normalized name: Omvoh
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal OMV vaccine administered as nose drops or nasal spray
Trial: 9554266
Drug: Nasal OMV
RxNorm normalized name: Omvoh
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal OMV vaccine
Trial: 9554266
Drug: Nasal OMV
RxNorm normalized name: Omvoh
DrugBank: Mirikizumab (DB14910)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal OMV vaccine with whole inactivated influenza virus
Trial: 2648723
Drug: Metformin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 0.5 g trice daily for 4 weeks
Trial: 25787877
Drug: 4-g ginger
RxNorm normalized name: WORMWOOD 0.4 g in 0.4 g / SAFFLOWER 0.4 g in 0.4 g / GINGER 0.4 g in 0.4 g BUCCAL PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-g ginger supplementation
Trial: 24439186
Drug: Alogliptin (ALO,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin (ALO, 25 mg, once daily) as monotherapy
Trial: 24439186
Drug: Alogliptin (ALO,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin (ALO, 25 mg, once daily) as add-on to metformin
Trial: 24439186
Drug: Alogliptin (ALO,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin (ALO, 25 mg, once daily) as add-on to pioglitazone ± metformin
Trial: 24439186
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) as monotherapy
Trial: 24439186
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) as add-on to metformin
Trial: 24439186
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) as add-on to pioglitazone ± metformin
Trial: 19624593
Drug: Butea superba
RxNorm normalized name: BUTEA SUPERBA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butea superba (BS) 100 mg
Trial: 18257943
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g cocoa powder dissolved in 250 ml whole milk (CC-M)
Trial: 18257943
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g cocoa powder dissolved in 250 ml water (CC-W)
Trial: 18257943
Drug: 250 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml whole milk
Trial: 16634954
Drug: Conventional chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chlorhexidine solution (0.2%; CHX)
Trial: 16634954
Drug: Chlorhexidine solution
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine solution with anti-discolouration system (0.2%, alcohol-free chlorhexidine solution (CSP))
Trial: 16634954
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (Pla)
Trial: 12372669
Drug: Nitrendipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (10 to 40 mg/day) with possible addition of enalapril (5 to 20 mg/day) or hydrochlorothiazide (12.5 to 25 mg/day)
Trial: 17595475
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac 0.1%
Trial: 2184557
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin (conventional treatment)
Trial: 363773
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of ascorbic acid
Trial: 363773
Drug: Lactose capsules
RxNorm normalized name: lactose Oral Capsule
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose capsules
Trial: 31748982
Drug: Argon plasma
RxNorm normalized name: argon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Argon plasma treatment (PAT)
Trial: 29699758
Drug: sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sildenafil 100 mg
Trial: 24837141
Drug: Traditional neuro-developmental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional neuro-developmental physical therapy program without orthotic management (Group A)
Trial: 24331774
Drug: Periodontal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal treatment with topical antibiotics
Trial: 24331774
Drug: No periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No periodontal treatment (control group)
Trial: 16377677
Drug: Posaconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole (200 mg four times a day or 400 mg twice a day)
Trial: 12823855
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) plus calcium and vitamin D3
Trial: 8292064
Drug: Loratadine syrup
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine syrup (5 or 10 mg QD)
Trial: 8292064
Drug: Terfenadine suspension
RxNorm normalized name: terfenadine Oral Suspension
DrugBank: Terfenadine (DB00342)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terfenadine suspension (30 mg b.i.d.)
Trial: 3492571
Drug: Various serological
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various serological assays of antibody to PRP
Trial: 3492571
Drug: Different antigen
RxNorm normalized name: TRICOPHYTON ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different antigen preparations used in assays
Trial: 18760066
Drug: Total Dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Dose Infusion of low molecular weight iron dextran
Trial: 18760066
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron supplementation (ferrous sulphate 200 mg three times a day)
Trial: 11957809
Drug: Recombinantly produced
RxNorm normalized name: Recombinate Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinantly produced TNF-α soluble receptor
Trial: 4008112
Drug: Propranolol retard
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Avlocardyl Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol retard 160 mg
Trial: 31702058
Drug: Mentalization-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-based treatment in groups (MBT-G)
Trial: 19663523
Drug: Armodafinil (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil (50, 100, 200, 250, 300 or 400 mg)
Trial: 17277001
Drug: Ibandronate (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (oral or intravenous) at different doses and for variable time intervals
Trial: 17277001
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of ibandronate
Trial: 8021734
Drug: 5 daily
RxNorm normalized name: Alberto VO5 Daily Revitalizing Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 daily 2-hour infusions of 100 mg/m2
Trial: 8021734
Drug: 8 daily
RxNorm normalized name: tobramycin 28 MG inhalation powder 8 Daily Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 daily 75-minute infusions of 62.5 mg/m2
Trial: 2595106
Drug: Aminophylline (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (6 mg/kg over 20 min, followed by 0.9 mg/kg/h)
Trial: 4402080
Drug: Indoramin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin (20 mg.)
Trial: 4402080
Drug: Indoramin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin (40 mg.)
Trial: 4402080
Drug: Indoramin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin (10 mg.)
Trial: 31647087
Drug: Daily red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily red wine vinegar ingestion for 8 weeks
Trial: 28391435
Drug: Low-power laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-power laser with low dose (30 mW, 10 J/cm2, 9 s per point, 810 nm)
Trial: 28391435
Drug: Low-power laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-power laser with high dose (100 mW, 40 J/cm2, 11 s per point, 810 nm)
Trial: 28391435
Drug: Low-power laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-power laser with low dose + Gluma Desensitizer
Trial: 28391435
Drug: Low-power laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-power laser with high dose + Gluma Desensitizer
Trial: 28391435
Drug: Low-power laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-power laser with low dose + Nd:YAG laser
Trial: 28391435
Drug: Low-power laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-power laser with high dose + Nd:YAG laser
Trial: 26333366
Drug: Peripheral G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral G‐CSF combined with IC BMC therapy
Trial: 26333366
Drug: Peripheral G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral G‐CSF
Trial: 26333366
Drug: Peripheral G‐CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral G‐CSF and IC serum
Trial: 21876298
Drug: FES-therapy combined
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FES-therapy combined with progressive limb loading
Trial: 19478489
Drug: Periodontal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal treatment (PT) during pregnancy
Trial: 12182772
Drug: Surgery, interstitial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine (BCNU)
Trial: 9440482
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) 0.1 IU/kg daily
Trial: 9440482
Drug: Prednisolone 25
RxNorm normalized name: prednisolone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 25 mg morning and evening
Trial: 9440482
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) plus Prednisolone
Trial: 7975785
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg b.i.d. (n = 25)
Trial: 7975785
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg b.i.d. (n = 25)
Trial: 28433211
Drug: Ketamine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine monotherapy (KM) 1 mg/kg i.v. (with up to three additional doses of 0.5 mg/kg each)